Ship the same API batch to the US and to the EU, and it can pass one market’s GMP review and stall in the other’s not because the chemistry changed, but because the paperwork behind it was built for only one regulator. Sponsors selecting a CRDMO for multi-market supply routinely discover this only after a filing is already in motion, when the fix is expensive, and the timeline is not forgiving.
FDA and EMA agree on far more than they disagree on. But the gaps between them are specific, well documented, and entirely avoidable with the right outsourcing partner and the right questions asked upfront.
The Shared Foundation
Both agencies anchor API GMP expectations in ICH Q7, the harmonized guideline for good manufacturing practice of active pharmaceutical ingredients. Impurity control under ICH Q3A and mutagenic impurity assessment under ICH M7 apply identically on both sides of the Atlantic. This shared base is why a well-run CRDMO can genuinely serve both markets from the same facility; the divergence is in framework, documentation, and oversight mechanics, not in the underlying science.
Where the Frameworks Diverge
Regulatory instrument. FDA GMP requirements for APIs sit in 21 CFR Parts 210 and 211, applied to drug substances through ICH Q7. EMA’s requirements are codified in EudraLex Volume 4, Part II, the EU’s GMP guide specifically for active substances. Different legal instruments mean different inspection checklists, even when the underlying principle is the same.
Master file system. In the US, a Drug Master File (DMF), typically Type II, holds confidential manufacturing information that FDA references during an ANDA or NDA review. The EU equivalent is the Active Substance Master File (ASMF), submitted to the EMA or national authorities in a different format, under different update procedures. A DMF is not automatically portable into an ASMF submission the dossiers must be built for each system.
The Qualified Person requirement. The EU requires a named Qualified Person (QP) to certify that each batch has been manufactured and tested in accordance with GMP and the marketing authorization before release. The US has no direct equivalent. For a CRDMO supplying EU markets, QP certification readiness is not optional; it is a structural requirement with no US parallel to fall back on.
Written Confirmation for imported active substances. Since 2013, active substances imported into the EU generally require a Written Confirmation from the exporting country’s regulatory authority, confirming the manufacturing site meets GMP standards equivalent to EU requirements unless the exporting country is on the EU’s equivalence list or the site has been directly inspected. This requirement has no US counterpart and has tripped up more than one otherwise well-qualified API supplier attempting to enter EU supply chains for the first time.
Inspection mechanics. FDA inspections can be announced or unannounced and are risk-based, prioritizing sites by product risk and inspection history. EU inspections are coordinated through national competent authorities, often as part of a marketing authorization review. Since 2017, the FDA-EU Mutual Recognition Agreement has allowed both sides to rely on each other’s GMP inspections for human medicines in covered scopes, reducing duplicate inspections, but it does not eliminate the need for site readiness against both frameworks, since scope and product coverage under the MRA are not universal.
Data integrity emphasis. Both regulators expect ALCOA+ principles, and both cite data integrity failures heavily in enforcement actions, but the specific guidance documents differ: FDA’s data integrity guidance versus MHRA’s GxP data integrity guidance, which EU inspectors reference closely even though the MHRA sits outside the EU post-Brexit.
A Checklist for Evaluating an Outsourcing Partner
Before committing to a CRDMO for multi-market API supply, confirm:
- The site has an active DMF filed with FDA and, separately, an ASMF structured for EU submission, not one dossier repurposed as the other
- QP certification support is available if EU release is required, either through the CRDMO or a named EU-based QP
- Written Confirmation status is clear: is the exporting country on the EU equivalence list, or has the specific site been inspected by an EU authority
- The site’s inspection history is transparent for both FDA and any relevant EU national authority, including whether it falls within the FDA-EU MRA scope
- Data integrity controls are documented against both FDA and MHRA/EU expectations, not just one
The Bottom Line
FDA and EMA GMP expectations converge on the science and diverge on the paperwork, the certifications, and the inspection mechanics that surround it. A CRDMO built to supply only one market will eventually surface that gap in the other, usually at the worst possible time. The right partner treats dual-market readiness as a standing capability, not a special request.
LAXAI Life Sciences maintains cGMP manufacturing facilities equipped with advanced technologies and capabilities to support small molecule APIs supplied to the US, Europe, and Japan markets, with regulatory support spanning IND filing through NDA, ANDA, and DMF filing within a fully integrated CRDMO framework built for multi-market compliance.
